Loading...
XSHG603676
Market cap558mUSD
Jan 10, Last price  
9.41CNY
1D
-3.19%
1Q
11.89%
IPO
7.42%
Name

Tibet Weixinkang Medicine Co Ltd

Chart & Performance

D1W1MN
XSHG:603676 chart
P/E
19.13
P/S
3.10
EPS
0.49
Div Yield, %
2.39%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
12.13%
Revenues
1.32b
-5.43%
342,297,569390,794,633440,233,687426,360,894420,381,506746,324,814740,963,155715,666,8071,033,622,5241,398,543,0271,322,649,286
Net income
214m
+20.94%
82,950,458106,735,936112,934,722114,915,837101,587,28673,435,93255,677,78658,424,81395,911,098176,958,342214,016,879
CFO
257m
+4.27%
88,588,900118,472,228114,468,946103,788,12563,300,67883,167,651106,340,781133,697,656170,688,769246,153,584256,672,272
Dividend
Jul 02, 20240.285 CNY/sh
Earnings
May 16, 2025

Profile

Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company's products include parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.
URL
http://www.wxkpharma.com/
IPO date
Jul 21, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,322,649
-5.43%
1,398,543
35.31%
Cost of revenue
1,061,741
1,121,662
Unusual Expense (Income)
NOPBT
260,908
276,881
NOPBT Margin
19.73%
19.80%
Operating Taxes
1,821
5,397
Tax Rate
0.70%
1.95%
NOPAT
259,087
271,485
Net income
214,017
20.94%
176,958
84.50%
Dividends
(97,839)
(69,626)
Dividend yield
2.19%
1.02%
Proceeds from repurchase of equity
(3,171)
BB yield
0.05%
Debt
Debt current
2,313
Long-term debt
7,638
6,959
Deferred revenue
5,254
Other long-term liabilities
34,479
23,140
Net debt
(962,991)
(797,049)
Cash flow
Cash from operating activities
256,672
246,154
CAPEX
(70,814)
Cash from investing activities
(389,212)
105,213
Cash from financing activities
(102,436)
FCF
231,607
261,893
Balance
Cash
894,748
806,322
Long term investments
75,881
Excess cash
904,496
736,395
Stockholders' equity
1,079,948
937,814
Invested Capital
474,147
497,903
ROIC
53.31%
59.62%
ROCE
18.88%
22.42%
EV
Common stock shares outstanding
428,034
429,102
Price
10.43
-34.48%
15.92
71.37%
Market cap
4,464,392
-34.65%
6,831,304
73.84%
EV
3,643,753
6,034,254
EBITDA
309,483
317,816
EV/EBITDA
11.77
18.99
Interest
342
190
Interest/NOPBT
0.13%
0.07%